Close
Go To Macao Polytechnic University

2014/2015

Fibulin-1 is epigenetically down-regulated and related with bladder cancer recurrence

BMC Cancer*, 2014,14:677
- IFR: Top 37.91% in Oncology

Author(s)Wei Xiao
Ji Wang
Heng Li
Ding Xia
Gan Yu
Weimin Yao
Yang Yang
Haibing Xiao
Bin Lang
Xin Ma
Xiaolin Guo
Wei Guan
Hua Xu/
Jihong Liu
Xu Zhang
Zhangqun Ye
Summary

Background

Bladder cancer is one of the most common cancers worldwide. Fibulin-1, a multi-functional extracellular matrix protein, has been demonstrated to be involved in many kinds of cancers, while its function in bladder cancer remains unclear. So here we investigated the expression and function of fibulin-1 in Bladder cancer.


Methods
We used real-time PCR, Western blot analysis and immunohistochemistry to determine the expression of fibulin-1 in Bladder cancer cells and patient tissues respectively. Methylation-specific PCR and quantitative sequencing were used to examine the methylation status of FBLN1 gene promoter. Eukaryotic expression plasmid and lentiviral vector were used to overexpress fibulin-1 in Bladder cancer cells 5637, HT-1376 to investigate its function in vitro and in vivo.


Results
We identified that fibulin-1 was significantly down-regulated in bladder cancer, and its dysregulation was associated with non-muscle-invasive bladder cancer (NMIBC) grade and recurrence. The promoter region of FBLN1 was generally methylated in bladder cancer cell lines and tissues, further investigation in patient tissues showed that the methylation status was associated with the fibulin-1 expression. Overexpression of fibulin-1 significantly suppressed tumor growth, induced tumor cell apoptosis, decreased cell motility, and inhibited angiogenesis in cultured bladder cancer cells and xenograft tumor in nude mice.


Conclusions
Altogether, our results indicated that fibulin-1 expression is associated with NMIBC grade and recurrence, it is epigenetically down-regulated and functions as a tumor suppressor gene and angiogenesis inhibitor in bladder cancer.


* With an impact factor among those of the top 37.91% of journals in Oncology

Top Top